Welcome to CDC Stacks | Rifampicin Resistance in Tuberculosis Outbreak, London, England - 15784 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Rifampicin Resistance in Tuberculosis Outbreak, London, England
  • Published Date:
    Jun 2005
  • Source:
    Emerg Infect Dis. 11(6):931-934.
Filetype[PDF - 248.75 KB]


Details:
No Related Documents.
You May Also Like:
  1. Scarlet Fever Upsurge in England and Molecular-Genetic Analysis in North-West London, 2014
    Personal Author:
    Turner, Claire E.; Pyzio, Marta; Song, Bonita; Lamagni, Theresa; Meltzer, Margie; Chow, J. Yimmy; Efstratiou, Androulla; Curtis, Sally; Sriskandan, Shiranee;
    Published:
    Jun 2016
    Source:
    Emerg Infect Dis. 22(6):1075-1078.
    Description:
    Scarlet fever notifications surged across the United Kingdom in spring 2014. Molecular epidemiologic investigation of Streptococcus pyogenes infections in North-West London highlighted increased emm4 and emm3 infections coincident with the upsurge. U...
    File Type:
    Filetype[PDF - 1.90 MB]
  2. Ongoing Measles Outbreak in Orthodox Jewish Community, London, UK
    Personal Author:
    Baugh, Vanessa; Figueroa, Jose; Bosanquet, Joanne; Kemsley, Philippa; Addiman, Sarah; Turbitt, Deborah;
    Published:
    Oct 2013
    Source:
    Emerg Infect Dis. 19(10):1707-1709.
    File Type:
    Filetype[PDF - 613.27 KB]
  3. Could a tuberculosis epidemic occur in London as it did in New York?
    Personal Author:
    Hayward, A. C.; Coker, R. J.;
    Published:
    2000 Jan-Feb
    Source:
    Emerg Infect Dis. 6(1):12-16.
    Description:
    In early 1999, more than 160 senior physicians, public health officials, and nurses met to discuss London's tuberculosis (TB) control program. The program was examined against the public health response of New York City's Bureau of Tuberculosis Contr...
    File Type:
    Filetype[PDF - 66.55 KB]
  4. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
    Personal Author:
    Heidebrecht, Christine L.; Podewils, Laura J.; Pym, Alexander; Mthiyane, Thuli; Cohen, Ted;
    Published:
    Apr 06 2016
    Source:
    PLoS One. 11(4).
    Description:
    Background : KwaZulu-Natal (KZN) has the highest burden of notified multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant (XDR) TB cases in South Africa. A better understanding of spatial heterogeneity in the risk of drug-resistanc...
    File Type:
    Filetype[PDF - 703.50 KB]
  5. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs
    Personal Author:
    Kurbatova, Ekaterina V.; Cavanaugh, J. Sean; Shah, N. Sarita; Wright, Abigail; Kim, HeeJin; Metchock, Beverly; Van Deun, Armand; Barrera, Lucia; Boulahbal, Fadila; Richter, Elvira; Martín-Casabona, Nuria; Arias, Fabiola; Zemanova, Ilona; Drobniewski, Francis; Silva, Anabela Santos; Coulter, Christopher; Lumb, Richard; Cegielski, J. Peter;
    Published:
    2012
    Source:
    Int J Tuberc Lung Dis. 16(3):355-357.
    Description:
    Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). R...
    File Type:
    Filetype[PDF - 120.90 KB]